60 Degrees Pharmaceuticals (SXTP) Competitors $1.33 -0.01 (-0.75%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.32 -0.01 (-0.38%) As of 08/1/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock SXTP vs. AEZS, PLRZ, SLXN, JBIO, SBFM, INAB, BCLI, CELZ, PPBT, and ARTLShould you be buying 60 Degrees Pharmaceuticals stock or one of its competitors? The main competitors of 60 Degrees Pharmaceuticals include Aeterna Zentaris (AEZS), Polyrizon (PLRZ), Silexion Therapeutics (SLXN), Jade Biosciences (JBIO), Sunshine Biopharma (SBFM), IN8bio (INAB), Brainstorm Cell Therapeutics (BCLI), Creative Medical Technology (CELZ), Purple Biotech (PPBT), and Artelo Biosciences (ARTL). These companies are all part of the "pharmaceutical products" industry. 60 Degrees Pharmaceuticals vs. Its Competitors Aeterna Zentaris Polyrizon Silexion Therapeutics Jade Biosciences Sunshine Biopharma IN8bio Brainstorm Cell Therapeutics Creative Medical Technology Purple Biotech Artelo Biosciences Aeterna Zentaris (NASDAQ:AEZS) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations. Do insiders and institutionals believe in AEZS or SXTP? 0.7% of Aeterna Zentaris shares are held by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. 0.1% of Aeterna Zentaris shares are held by insiders. Comparatively, 10.3% of 60 Degrees Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate AEZS or SXTP? 60 Degrees Pharmaceuticals has a consensus price target of $7.00, suggesting a potential upside of 426.32%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Aeterna Zentaris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aeterna Zentaris 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.0060 Degrees Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has preferable earnings & valuation, AEZS or SXTP? 60 Degrees Pharmaceuticals has lower revenue, but higher earnings than Aeterna Zentaris. Aeterna Zentaris is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAeterna Zentaris$2.37M2.89-$16.55M-$14.86-0.2660 Degrees Pharmaceuticals$300K6.52-$7.95M-$50.41-0.03 Is AEZS or SXTP more profitable? Aeterna Zentaris has a net margin of -760.32% compared to 60 Degrees Pharmaceuticals' net margin of -1,947.30%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Aeterna Zentaris' return on equity.Company Net Margins Return on Equity Return on Assets Aeterna Zentaris-760.32% -83.45% -45.76% 60 Degrees Pharmaceuticals -1,947.30%N/A -174.90% Does the media favor AEZS or SXTP? In the previous week, 60 Degrees Pharmaceuticals had 3 more articles in the media than Aeterna Zentaris. MarketBeat recorded 3 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Aeterna Zentaris. Aeterna Zentaris' average media sentiment score of 0.00 beat 60 Degrees Pharmaceuticals' score of -0.33 indicating that Aeterna Zentaris is being referred to more favorably in the media. Company Overall Sentiment Aeterna Zentaris Neutral 60 Degrees Pharmaceuticals Neutral Which has more volatility & risk, AEZS or SXTP? Aeterna Zentaris has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.72, suggesting that its stock price is 172% more volatile than the S&P 500. Summary60 Degrees Pharmaceuticals beats Aeterna Zentaris on 11 of the 16 factors compared between the two stocks. Get 60 Degrees Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SXTP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SXTP vs. The Competition Export to ExcelMetric60 Degrees PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.96M$2.50B$5.53B$9.37BDividend YieldN/A1.80%4.74%4.12%P/E Ratio-0.038.9728.8823.79Price / Sales6.52687.56440.8796.30Price / CashN/A155.1435.0757.18Price / Book-0.214.838.255.54Net Income-$7.95M$31.62M$3.25B$259.88M7 Day Performance1.53%-5.28%-3.75%-4.67%1 Month Performance-45.93%4.38%4.26%4.40%1 Year Performance95.73%-2.49%25.83%17.91% 60 Degrees Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SXTP60 Degrees Pharmaceuticals2.1457 of 5 stars$1.33-0.7%$7.00+426.3%+93.5%$1.96M$300K-0.033Analyst ForecastShort Interest ↑AEZSAeterna ZentarisN/A$4.19-3.2%N/A-34.7%$7.51M$2.37M-0.2820PLRZPolyrizonN/A$1.41+55.3%N/AN/A$7.51MN/A0.00N/ANews CoverageGap UpHigh Trading VolumeSLXNSilexion TherapeuticsN/A$0.84+1.7%$5.00+495.9%N/A$7.29MN/A0.00N/ANews CoverageUpcoming EarningsStock SplitJBIOJade Biosciences1.8331 of 5 stars$8.60-1.0%$15.00+74.4%N/A$7.22MN/A-0.1420SBFMSunshine Biopharma1.7121 of 5 stars$1.57+0.6%$15.00+855.4%+456.0%$7.16M$34.87M-0.013Short Interest ↑INABIN8bio3.2577 of 5 stars$2.36+2.6%$180.00+7,527.1%-91.7%$7.15MN/A-0.1720BCLIBrainstorm Cell Therapeutics1.7416 of 5 stars$0.73-2.0%N/A-86.6%$7.13MN/A-0.2240Gap DownCELZCreative Medical Technology0.5058 of 5 stars$2.76+0.6%N/A-14.1%$7.13M$14K-0.725News CoverageUpcoming EarningsShort Interest ↑PPBTPurple Biotech2.2344 of 5 stars$2.68-3.6%$33.00+1,131.3%N/A$7.11MN/A-1.0520ARTLArtelo Biosciences2.2361 of 5 stars$12.92-11.2%$25.00+93.5%+25.9%$7.11MN/A-0.725Short Interest ↑ Related Companies and Tools Related Companies AEZS Competitors PLRZ Competitors SLXN Competitors JBIO Competitors SBFM Competitors INAB Competitors BCLI Competitors CELZ Competitors PPBT Competitors ARTL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SXTP) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 60 Degrees Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 60 Degrees Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SXTP Stock Alerts